Three in and three out on damaging day for Dyne

3 September 2024

A series of key leadership changes have been announced on Tuesday at Dyne Therapeutics (Nasdaq: DYN), a muscle disease company developing therapeutics for people living with genetically-driven diseases.

The executive changes were announced on the same day as important Dyne clinical data. Shares in the company had dropped by nearly a third by lunchtime.

Doug Kerr (pictured above) has been appointed chief medical officer (CMO) at the Boston-based firm, succeeding Wildon Farwell, who is stepping down from his role.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK